Navigation Links
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Date:6/11/2008

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm.

The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in AR patients outside of allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.

"This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data," said Dr. Yuval Cohen, president of Morria. "We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combine
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
(Date:9/15/2014)... FRANCISCO , Sept. 15, 2014 ... studies presented at the American Society for Radiation ... its Decipher® Prostate Cancer Classifier, a genomic test ... influence treatment decisions and improve patient outcomes for ... These presentations follow a recently published study that ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data on the ... report provides value, in millions of US dollars, ... dollars) within market segments Invasive Body Contouring Devices ... Radio Frequency-Assisted Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:9/16/2014)... in cancer patients suffering from malignant spinal cord compression ... of radiation therapy (RT), compared to patients who receive ... according to research presented today at the American Society ... Malignant spinal cord compression (MSCC) is a complication of ... a tumor,s secondary deposit presses on the spinal cord ...
(Date:9/16/2014)... Umpires and judges are the unwitting focus of some ... and gymnasts to improve their performance in competition, thanks ... researcher. , Dr Daniel Greenwood, from QUT,s Institute of ... Academy of Sport Centre of Excellence for Applied Sport ... in sports such as cricket, long jump, triple jump ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 Transparency ... states that the global facial care market is expected ... 2019. The report, titled ‘Facial Care Market (By Product ... Face Wash, Cleansing Wipes, Serums and Masks and Others ... Size, Share, Growth, Trends and Forecast 2013 – 2019,’ ...
(Date:9/16/2014)... Whatisfinalexpenseinsurance.com has released a new blog post ... seniors. , Finding affordable life insurance for senior citizens ... the insurance market has moved online. The newly released ... use when shopping for life coverage. , Having ... financial security for vulnerable family members. Clients can use ...
Breaking Medicine News(10 mins):Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Getting the jump on competitors: QUT study 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2
... life expectancy, study finds , TUESDAY, Feb. 23 ... MRI appears to be a cost-effective way to improve ... cancer, U.S. researchers say. , In the new study, ... in Boston, and colleagues used statistical modeling to compare ...
... ... ... ... ...
... stress hormone levels in adolescent boys and girls but ... researchers. Early treatment of depression could help reduce stress ... "This is the first time cortisol reactivity has ... obesity in girls," said Elizabeth J. Susman, the Jean ...
... ... ... , ... , , , , ...
... LOUIS -- The extract from a vegetable that is common ... of events that kills breast cancer cells and prevents them ... Ratna Ray, Ph.D., professor in the department of pathology at ... that the extract from the bitter melon she cooks in ...
... ... ... ... ...
Cached Medicine News:Health News:Mammogram Plus MRI Seems Cost-Effective in High-Risk Women 2Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 2Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 3Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 4Health News:Stress hormone, depression trigger obesity in girls 2Health News:Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference 2Health News:Bitter melon extract attacks breast cancer cells 2Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 2Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 3
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
19 Gauge. Reusable. Block of 4 each....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: